The present study was aimed to develop compression coated tablets of diclofenac sodium (75mg) in the inner core and misoprostol (200 mg) as the outer shell for the effective treatment of rheumatoid arthritis as this dosing frequency is not available in the market yet. Diclofenac sodium inner tablet was manufactured by wet granulation and its enteric coating was applied by Eudragit L 100-55, Isopropyl Alcohol and Opadry II Blue 85 F205034. While immediate-release misoprostol outer shell was also manufactured by wet granulation and coated by Opadry white and Polyethylene glycol 6000. Design of experiment® software was used for formulation design and optimization. Quality attributes such as tablet weight, hardness, disintegration time, percent drug dissolution and assay were performed as per official methods and satisfactory results were reported. Physical and chemical stability of selected formulations was evaluated following the ICH guidelines for accelerated stability testing. The compressional analysis of optimized formulation was performed to check the optimum compression pressure to obtain a stable formulation. Based on satisfactory quality attributes; formulation DF9MF7 was successfully developed as compression coated tablet with calculated shelf life of 4.8years. Compression coated tablets comprising of enteric coated diclofenac sodium as inner core and misoprostol as outer shell were successfully developed by wet granulation.

Aim: To look for the presence of depression and anxiety among patients suffering from mild to moderate COVID-19 disease. Methodology: This cross sectional study was conducted at Department of Medicine, Pakistan Ordinance Factory (POF) Hospital Wah Cantt from 1st April 2020 to 30th September 2020. Patients presenting to Pakistan Ordinance Factory (POF) Hospital Wah Cantt with relevant symptoms and tested positive on polymerase chain reaction for COVID-19 were included in the study. Hospital anxiety and depression scale (HADS) was administered to look for the presence and severity of anxiety and depression among the study participants. Results: Total 101 patients were included in the study, 76.2% were male while 23.8% were female. Mean age of the patients was 53.50 ±13.281years.Out of 101 patients, 33.7% did not show any sign of anxiety and 42.6% showed borderline anxiety while 23.8% had confirmed anxiety. Depression was not found in 72.3%, borderline depressive symptoms were present in 25.7%, while 2% had confirmed depression. Conclusion: Depression and anxiety were common findings among patients admitted in hospital with COVID 19. Anxiety was more common than depression in these patients. Borderline anxiety and depression were found in most of the patients which may need formal psychiatric consultation for exact diagnosis. Keywords: Anxiety; covid-19; depression, Pakistan